Satellos Bioscience's latest earnings report shows a significant shortfall, raising concerns among investors.
In its most recent earnings report, Satellos Bioscience Inc. (MSCL.TO) reported an earnings per share (EPS) of -0.7807 for the fiscal period ending June 30, 2026. This fell short of analysts' estimates by 36.96%. This miss continues a trend of disappointing earnings for the company, which has only beaten estimates in one of its last four quarters.
Recent earnings trend
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeAdvertisement
Market cap
$278.72M
52W high
$18.98
52W low
$6.84
1W change
-2.55%
Beta
1.17
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 32.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+32.0% Upside
Current Price
C$13.38
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
68.3%
Annualized
90-Day Vol
83.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$16.00
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$14.20 | C$11.22 – C$17.97 |
| 60 trading days | C$15.07 | C$10.80 – C$21.03 |
| 90 trading days | C$16.00 | C$10.64 – C$24.06 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 1 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | -0.7807 | -0.5700 | -37.0% |
| 2026-03-31 | 2026-05-13 | -0.7294 | -0.5900 | -23.6% |
| 2025-12-31 | 2026-03-27 | -0.6900 | -0.5000 | -38.0% |
| 2025-09-30 | 2025-11-14 | -0.5000 | -0.6600 | +24.2% |
| 2025-06-30 | 2025-08-13 | -0.5000 | -0.6000 | +16.7% |
| 2025-03-31 | 2025-05-13 | -0.6700 | -0.6000 | -11.7% |
Advertisement
Investor takeaway: With a market cap of about CA$278.72 million, Satellos is navigating a tough financial landscape. Investors should consider the implications of this earnings miss alongside the company's ongoing clinical trials and recent FDA fast track designation, which could impact future performance.
Bull case
The recent FDA fast track designation for Satellos's drug SAT-3247 offers hope for quicker development and approval. This could significantly boost the company's market position and revenue potential in the long run.
Bear case
The large earnings miss and the company’s track record of disappointing financial results raise concerns about its operational efficiency and market strategy. This could affect investor confidence and the stability of its stock price.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
